Bayer Stock Rallies as Next-Gen Blood Thinner Achieves Phase 3 Success
Bayer's stock experienced a rally following the successful Phase 3 trial of its next-generation blood thinner.
The positive trial outcome boosted investor confidence in Bayer's pharmaceutical pipeline.
This development comes amid steady Q3 2025 growth, with a 1% increase in net sales and strong performance in key products like Nubeqa and Kerendia.
Bayer reaffirmed its full-year 2025 outlook, citing innovation and efficiency as drivers of future growth.